Testing a New Injection for Lupus (SLE)
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lupus (SLE) based on standard guidelines.
- Your lupus is moderately to severely active (score of 8 or more on a doctor's scale).
- You have tried standard lupus treatments (like steroids, hydroxychloroquine, or other medications) but they didn't work well, caused problems, or your lupus came back.
- You have a positive blood test for lupus-related antibodies (ANA or anti-dsDNA).
- You have not used certain lupus medications (like rituximab, belimumab, or JAK inhibitors) within the past few weeks or months.
- You do not have active infections like tuberculosis, HIV, hepatitis B or C, or other serious health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This study tests a new experimental drug called SCTC21C in people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. The trial aims to see if this drug can help reduce lupus symptoms and inflammation when added to standard treatments.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.